Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model
November 11th, 2022
1.9K views
This protocol provides a step-by-step procedure for executing multiple intravenous bolus dose administration and invasive hemodynamic monitoring in mice. Investigators can use this protocol for future therapeutic compound screening for pulmonary artery hypertension.
Overview
This protocol provides a detailed procedure for multiple intravenous bolus dosing and invasive hemodynamic monitoring in mice. It is designed for researchers interested in developing treatments for pulmonary artery hypertension.
Key Study Components
Area of Science
- Pharmacology
- Cardiovascular research
- Animal models
Background
- Intravenous administration is crucial for compounds requiring direct bloodstream delivery.
- Accurate hemodynamic assessment is essential in pulmonary arterial hypertension studies.
- Mouse models are commonly used for testing therapeutic compounds.
- Successful administration techniques require practice and precision.
Purpose of Study
- To provide a protocol for intravenous bolus dosing in mice.
- To facilitate hemodynamic monitoring in pulmonary artery hypertension models.
- To support drug development and screening efforts.
Methods Used
- Multiple intravenous bolus dosing via mouse jugular vein.
- Arterial and right ventricular catheterizations for hemodynamic assessment.
- Monitoring blood pressure and other vital parameters.
- Utilizing a hypoxia pulmonary arterial hypertension model.
Main Results
- Successful execution of intravenous bolus injections.
- Accurate hemodynamic measurements obtained.
- Protocol demonstrated effectiveness for compound screening.
- Findings support future therapeutic research in pulmonary artery hypertension.
Conclusions
- The protocol is a valuable tool for researchers in pharmacology.
- It enhances the understanding of drug administration routes.
- Facilitates advancements in treatments for pulmonary artery hypertension.
Frequently Asked Questions
What is the main focus of this protocol?
The protocol focuses on intravenous bolus dosing and hemodynamic monitoring in mice.
Why is intravenous administration important?
It allows for direct delivery of compounds into the bloodstream, which is crucial for accurate dosing.
What model is used in this study?
The study uses a hypoxia pulmonary arterial hypertension model in mice.
What are the key techniques involved?
Key techniques include jugular vein bolus injection and arterial catheterization.
How can this protocol aid drug development?
It provides a standardized method for screening therapeutic compounds in animal models.
What are the expected outcomes of this protocol?
Expected outcomes include successful drug administration and accurate hemodynamic data.
Executive Industry Relevance
Robust intravenous bolus dosing and invasive hemodynamic assessment in the hypoxia-induced mouse PAH model enable high-confidence evaluation of candidate therapeutics targeting pulmonary vascular disease. This workflow supports predictive compound screening and quantitative endpoint measurement, directly informing early-stage portfolio triage and target validation. The protocol's reproducibility and quantitative outputs are critical for translational continuity from discovery through preclinical assessment.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables rigorous interrogation of therapeutic hypotheses in a disease-relevant in vivo system.
- Supports functional target validation by quantifying hemodynamic responses to candidate compounds.
- Facilitates mechanistic de-risking through direct measurement of right ventricular systolic pressure changes.
- Provides quantitative data to inform predictive confidence and early go/no-go decisions.
Screening & Assay Development
- Establishes a validated platform for compound administration and response measurement in mouse models.
- Delivers standardized, reproducible hemodynamic endpoints suitable for comparative screening.
- Enables scalability for multi-compound evaluation and platform reuse across PAH research programs.
- Supports reliable assessment of compound efficacy in vivo.
Translational & Preclinical Research
- Aligns preclinical endpoints with human PAH pathophysiology for translational biomarker development.
- Ensures continuity of quantitative hemodynamic data from discovery through preclinical validation.
- Reduces translational risk by modeling clinically relevant disease mechanisms and responses.
- Supports risk-adjusted advancement of lead compounds based on robust in vivo data.
Pipeline & Workflow Integration
This protocol integrates into the discovery-to-preclinical continuum, bridging early compound screening with translational in vivo validation in PAH models.
- Discovery Biology: Provides a platform for hypothesis testing and mechanistic clarification in pulmonary vascular disease.
- Screening: Delivers reproducible, quantitative hemodynamic outputs for compound comparison.
- Analytics: Enables direct measurement of right ventricular and systemic blood pressure as decision-driving endpoints.
- Translational Research: Aligns preclinical data with clinical PAH manifestations for biomarker and efficacy assessment.
- Enterprise Reuse: Offers a standardized, adaptable workflow for diverse compound and disease model applications.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in PAH drug discovery.
- Operational Value: Standardizes compound administration and endpoint measurement for reproducibility and scalability.
- Strategic Value: Improves early go/no-go decisions and capital efficiency by providing robust in vivo data.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of candidate therapeutics.
Implementation Considerations
- Requires technical expertise in mouse surgery and hemodynamic catheterization.
- Demands specialized instrumentation for pressure measurement and data acquisition.
- Necessitates cross-team standardization of dosing and measurement protocols.
- Adaptable to other mouse disease models with intravenous compound administration needs.
- Technical complexity may limit throughput and requires extensive operator training.
Biopharma FAQs
Why does null hypothesis testing matter for hemodynamic response validation?
Null hypothesis testing in this protocol enables objective assessment of whether observed hemodynamic changes after compound administration are statistically significant, supporting rigorous target validation and reducing false positives in early discovery.
How does independent variable isolation fit intravenous bolus dosing studies?
Isolating the compound as the independent variable during multiple IV bolus dosing ensures that measured hemodynamic effects can be attributed directly to the intervention, strengthening mechanistic interpretation and pipeline decision-making.
What do quantitative right ventricular pressure measurements enable in PAH models?
Quantitative right ventricular systolic pressure measurements provide actionable endpoints for comparing compound efficacy, enabling data-driven prioritization and supporting translational alignment with clinical PAH outcomes.
Why are replication requirements critical for cross-functional PAH research?
Replication of IV dosing and hemodynamic assessment protocols ensures reproducibility across teams, facilitating reliable data sharing and collaborative advancement of candidate therapeutics in multi-site R&D environments.
What statistical analysis capabilities are required before implementing pressure data endpoints?
Robust statistical analysis tools are needed to compare pressure data across experimental groups, assess significance, and support confident go/no-go decisions in the PAH drug discovery pipeline.
Chapters in this video
0:00
Introduction
1:06
Intravenous Bolus Injection via the Jugular Vein
2:35
Blood Pressure Measurement
3:18
Systemic Blood Pressure Measurement
5:35
Right Ventricular Systolic Pressure Measurement in a Mouse with Pulmonary Hypertension
7:18
Results: Blood Pressure Analysis in Hypoxic Mice
8:16
Conclusion
